Erin Andrews, host of ABC’s Dancing with the Stars, reporter
with Fox Sports and cervical cancer survivor, will be a special
guest at a forum designed to provide patients and families with an
overview of the impact of cervical cancer, available support
programs and the need for new, innovative treatments.
“Latest Advances in Cervical Cancer: Living with the Disease,”
an event hosted by Gilda’s Club South Florida in collaboration with
Sylvester Comprehensive Cancer Center, part of the University of
Miami Health System, and sponsored by Advaxis, Inc. (NASDAQ:ADXS),
will be held Thursday, May 18, at 5 p.m. at the Diplomat Beach
Resort in Hollywood, Fla. Space is limited and registration is
required. Please register at www.advaxis.com/forum2017 on or before
Tuesday, May 16.
The event features Ms. Andrews, who will discuss her life
experiences and career, including her journey to becoming a
cervical cancer survivor. Ms. Andrews was diagnosed and treated
early during the 2016 NFL season. Erin will tell her story in a
moderated discussion and Q&A. The event program also includes
leading oncologists, researchers and patient advocates who will
discuss the details of cervical cancer, new advances in care and
programs to support patients and families fighting this
disease.
Cervical cancer is the fourth most common cancer in women
worldwide, and each year about 13,000 women in the United States
are diagnosed. Annually, approximately 4,200 U.S. lives are lost to
the disease. More than 90 percent of cervical cancer cases can be
attributed to strains of the human papillomavirus (HPV). HPV is now
the most common sexually transmitted infection in the United
States, with recently published research showing that 39.9 percent
of U.S. women are infected. Over the past 30 years there has only
been one new product approved for the treatment of cervical cancer,
and patients and families need additional support and new
treatments.
Sylvester Comprehensive Cancer Center offers patients with
cervical cancer access to available treatment options including
chemo-radiation therapy. The cancer center is also a trial site for
Advaxis’ global Phase 3 AIM2CERV trial, which is evaluating
axalimogene filolisbac in patients with high-risk, locally advanced
cervical cancer. Axalimogene filolisbac, a targeted Listeria
monocytogenes (Lm)-based immunotherapy, is the only known
cancer immunotherapy agent shown in preclinical studies to alert
the body’s immune system to the presence of cancer, diminish that
cancer’s natural defense mechanisms and then rally the body’s
killer T cells to attack the cancer. Currently, AIM2CERV is the
only active industry-sponsored global phase 3 clinical trial in
cervical cancer.
Axalimogene filolisbac and other advances in cervical cancer
will be discussed during the event on May 18. The speaking program,
which will be followed by a reception, also includes:
- Impact of Cervical Cancer; Erin Kobetz,
Ph.D., MPH, Sylvester Comprehensive Cancer Center
- Immunotherapies; Marilyn Huang, M.D.,
Sylvester Comprehensive Cancer Center
- Filling Unmet Need: Advancements in
Therapies; Brian M. Slomovitz, M.D., Sylvester Comprehensive Cancer
Center
- Survivorship & Patient Support;
Teresa Neira, LCSW, Ph.D., Sylvester Comprehensive Cancer Center
and Stacey Balkanski, LCSW, Program Director, Gilda’s Club
- Moderated Session: Life Experience with
Cervical Cancer and Q&A with Erin Andrews; moderated by Laurie
Stein
About Cervical CancerCervical cancer is the fourth most
common cancer affecting women worldwide. An estimated 13,000 new
cases will be diagnosed in the United States in 2016, and 4,100
women will have this disease as their cause of death, according to
the National Cancer Institute. Decades of research have shown that
persistent HPV infection, particularly with high-risk virus types
such as HPV-16 and HPV-18, is the most important factor in the
development of cervical cancer. The prognosis for women with
advanced and recurrent cervical cancer remains poor, with median
survival of only six to seven months following initiation of
palliative treatment with chemotherapy. According to the American
Cancer Society, the five-year survival rate for Stage IV disease is
at 15 to 16 percent. There is no approved therapy following failure
of first-line treatment, and there has been limited advancement in
developing new therapeutics for advanced cervical cancer over the
last 30 years.
About Gilda’s ClubGilda’s Club, was named in honor of
comedian Gilda Radner, who lost her battle with ovarian cancer in
1989 at 42 years old. Gilda’s Club South Florida’s mission is to
create welcoming communities of free support for everyone living
with cancer – men, women, teens, and children – along with their
families and friends. Our innovative program is an essential
complement to medical care, providing networking and support
groups, workshops, education and social activities. Gilda’s Club
has been providing programs to those living with cancer and their
family and friends in South Florida since 1997.
About Sylvester Comprehensive Cancer CenterSylvester
Comprehensive Cancer Center, part of UHealth – the University of
Miami Health System and the University of Miami Miller School of
Medicine, is among the nation’s leading cancer centers and South
Florida's only Cancer Center of Excellence. A 2015 study by
Memorial Sloan Kettering Cancer Center, published in The Journal of
the American Medical Association, showed that cancer patients
treated at Sylvester have a 10 percent higher chance of survival
than those treated at nearly any other cancer center in the nation.
With the combined strength of more than 120 cancer researchers and
130 cancer specialists, Sylvester discovers, develops and delivers
more targeted therapies, providing the next generation of cancer
clinical care – precision cancer medicine – to each patient. Our
comprehensive diagnostics, coupled with teams of scientific and
clinical experts who specialize in just one type of cancer, enable
us to better understand each patient’s individual cancer and
develop treatments that target the cells and genes driving the
cancer's growth and survival, leading to better outcomes. At
Sylvester, patients have access to more treatment options and more
cancer clinical trials than most hospitals in the southeastern
United States. To better serve current and future patients,
Sylvester has a network of conveniently located outpatient
treatment facilities in Miami, Kendall, Hollywood, Plantation,
Deerfield Beach, Coral Springs, and Coral Gables. For more
information, visit sylvester.org.
About Advaxis, Inc.Located in Princeton, N.J., Advaxis,
Inc. is a biotechnology company developing multiple cancer
immunotherapies based on its proprietary Lm Technology™.
The Lm Technology, using bioengineered live
attenuated Listeria monocytogenes (Lm) bacteria, is the
only known cancer immunotherapy agent shown in preclinical studies
to both generate cancer fighting T cells directed against cancer
antigens and neutralize Tregs and myeloid-derived suppressor cells
(MDSCs) that protect the tumor microenvironment from immunologic
attack and contribute to tumor growth. Advaxis'
lead Lm Technology immunotherapy, axalimogene filolisbac,
targets HPV-associated cancers and is in clinical trials for three
potential indications: Phase 3 in invasive cervical cancer, Phase 2
in head and neck cancer, and Phase 2 in anal cancer. The FDA has
granted axalimogene filolisbac orphan drug designation for each of
these three clinical settings, as well as Fast Track designation
for adjuvant therapy for HRLACC patients and a SPA for the Phase 3
AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also
been classified as an advanced therapy medicinal product for the
treatment of cervical cancer by the EMA’s CAT. Advaxis has two
additional immunotherapy products: ADXS-PSA in prostate cancer and
ADXS-HER2 in HER2 expressing solid tumors, in human clinical
development. In addition, Advaxis and Amgen are developing
ADXS-NEO, an investigational cancer immunotherapy treatment
designed to activate a patient's immune system to respond against
the unique mutations, or neoepitopes, contained in and identified
from each individual patient's tumor, with plans to enter the
clinic in 2017.
To learn more about Advaxis, visit www.advaxis.com and
connect on Twitter, LinkedIn, Facebook,
and YouTube.
Advaxis Forward-Looking StatementThis press release
contains forward-looking statements, including, but not limited to,
statements regarding Advaxis’ ability to develop the next
generation of cancer immunotherapies, and the safety and efficacy
of Advaxis’ proprietary immunotherapy, axalimogene filolisbac.
These forward-looking statements are subject to a number of risks
including the risk factors set forth from time to time in Advaxis’
SEC filings including, but not limited to, its report on Form 10-K
for the fiscal year ended October 31, 2016, which is available
at http://www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law.
You are cautioned not to place undue reliance on any
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170505005491/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
Affairsheber@advaxis.comorMedia:JPA Health
CommunicationsDavid Connolly, 617-657-1301dconnolly@jpa.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024